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Summary
Recent reports have implicated the “thermolabile”
(T) variant of methylenetetrahydrofolate reductase
(MTHFR) in the causation of folate-dependent neural
tube defects (NTDs). We report herein the largest genetic
study of NTD cases ( ) and families ( )n  271 n  218
to date, establishing that, in Ireland, the “TT” genotype
is found in 18.8% of cases versus 8.3% of controls (odds
ratio 2.57; confidence interval [CI] 1.48–4.45; P 
). The maternal and paternal TT genotypes have.0005
intermediate frequencies of 13.8% and 11.9%, respec-
tively, indicating that the predominant MTHFR-related
genetic effect acts via the TT genotype of the developing
embryo. Analysis of the 218 family triads of mother,
father, and affected child with log-linear models supports
this interpretation, providing significant evidence that
the case TT genotype is associated with NTDs (P 
) but no evidence of a maternal TT genotypic effect.02
( ). The log-linear model predicted that the riskP  .83
of NTDs conferred by the case TT genotype is 1.61 (CI
1.06–2.46), consistent with the paramount importance
of the case TT genotype in determining risk. There is
no compelling evidence for more than a modest addi-
tional risk conferred by a maternal TT genotype. These
results favor a biological model of MTHFR-related
NTD pathogenesis in which suboptimal maternal folate
status imposes biochemical stress on the developing em-
bryo, a stress it is ill-equipped to tolerate if it has a TT
genotype.
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Introduction
Neural tube defects (NTDs), in particular spina bifida
and anencephaly, are among the most common severe
congenital malformations and represent a long-term
public health burden in both social and economic terms
(Centers for Disease Control 1989). Although the cause
of NTDs remains poorly understood, inheritance of pre-
disposing genetic factors is generally considered to be an
important contributor (Little and Nevin 1992). Women
who have already given birth to an affected child have
a 10- to 15-fold increased risk that a subsequent child
will have an NTD (Little 1992), suggesting that there is
a strong maternal and/or familial pathogenic compo-
nent. A series of studies over the past decade have es-
tablished that folic acid supplements taken periconcep-
tionally can greatly reduce (up to 72%) a woman’s risk
of both NTD occurrence and NTD recurrence in her
offspring (MRC Vitamin Study Research Group 1991;
Czeizel and Dudas 1992). Because most women carrying
affected embryos have plasma and red blood cell folate
levels well above the clinically deficient range (Kirke et
al. 1993; Daly et al. 1995), it is apparent that folic acid
does not act by correcting a simple severe nutritional
deficiency. In the early 1990s, several studies established
that women carrying embryos with NTDs (Kirke et al.
1993; Mills et al. 1995) and women who have given
birth to affected infants (Steegers-Theunissen et al. 1991,
1994) have significantly elevated plasma levels of the
amino acid homocysteine (i.e., they are hyperhomocys-
teinemic) and significantly reduced plasma folate and
vitamin B12 concentrations. Of the five enzymes that con-
trol homocysteine levels—cystathionine b-synthase
(CbS), betaine methyltransferase, S-adenosyl homocy-
steine hydrolase, methionine synthase (MS), and 5,10-
methylenetetrahydrofolate reductase (MTHFR)—the
latter two are folate dependent, and genetic variants
thereof are obvious candidates as risk factors involved
in the causation of folate-preventable NTDs. To date,
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studies of the MS (Morrison et al. 1997; van der Put et
al. 1997b) and CbS (Ramsbottom et al. 1997) genes have
failed to identify any variants that are significantly as-
sociated with NTDs.
MTHFR regulates the methionine synthase–mediated
remethylation of homocysteine to methionine by cata-
lyzing the rate-limiting reduction of 5,10-methylene-
tetrahydrofolate to the methyl group donor 5-methyl-
tetrahydrofolate (Scott and Weir 1994). Severe defi-
ciency of the enzyme, which is critical in controlling
basal concentrations of homocysteine, results in mas-
sively elevated plasma homocysteine concentrations and
homocystinuria, a syndrome characterized by multiple
physical, developmental, and cognitive defects (Rosen-
blatt 1989). Kang and colleagues (1988) identified a
form of MTHFR, in ∼5% of the white population, that
is biochemically “thermolabile” in that its residual ac-
tivity after incubation at 46C for 5 min is significantly
less than that of the wild-type enzyme. Individuals with
the thermolabile enzyme were subsequently shown to be
at higher risk for hyperhomocysteinemia (Engbersen et
al. 1995). After MTHFR cDNA was cloned (Goyette et
al. 1994), the mutation underlying the thermolabile iso-
form was identified as a CrT transition at nucleotide
677 (Frosst et al. 1995) that mandates the replacement
of an alanine by a valine in a functionally important
region of the molecule. Several recent studies have es-
tablished that individuals with the thermolabile “TT”
genotype are at greatly increased risk of being hyper-
homocysteinemic, and those who have this phenotype
have significantly reduced plasma folate levels (van der
Put et al. 1995; Harmon et al. 1996; Jacques et al. 1996).
On the basis of the findings of the above-mentioned
studies, a consensus is emerging that TT homozygotes
have aberrant folate metabolism and an increased re-
quirement for this nutrient. Consequently, individuals
with the TT genotype may be at particular risk of hy-
perhomocysteinemia and homocysteine-related diseases
when their plasma folate concentrations are toward the
low end of the normal range.
Given the prevalence of hyperhomocysteinemia and
low folate status in mothers of offspring with NTDs,
there are sound theoretical grounds to expect that the
TT genotype would be overrepresented in individuals
with NTDs and in mothers who have had a child with
an NTD. We (Whitehead et al. 1995) and van der Put
et al. (1995) independently reported that such was the
case in the Irish and Dutch populations, respectively.
Studies by Ou et al. (1996), Kirke et al. (1996), and
Christensen et al. (1997) have supported this associa-
tion; however, others (de Franchis et al. 1995; Papape-
trou et al. 1996; Wilcken and Wang 1996; Mornet et
al. 1997; Speer et al. 1997; Koch et al. 1998) have pub-
lished negative studies and/or questioned the validity of
the conclusion that the TT genotype confers risk of
NTDs. Some of the latter authors have challenged the
reliability of the data supporting a positive association,
on the grounds that they were derived from studies that
involved relatively few subjects and potentially poorly
matched controls and thus were prone to sampling er-
rors. They further suggested that the allele transmission
disequilibrium test (TDT) for linkage (Spielman et al.
1993) is a more robust and appropriate method for val-
idating genetic hypotheses, such as the association of the
thermolabile variant of MTHFR with NTD risk, since
it eliminates concerns regarding the selection of appro-
priately matched controls and the distortions of gene
frequencies that may be produced by underlying ethnic
heterogeneity and consequent population stratification.
Herein we report the largest genetic association study
of NTDs to date and present evidence that supports our
initial estimates (Whitehead et al. 1995) of the level of
risk conferred by the case MTHFR TT genotype. In ad-
dition, we confirm the pathogenic involvement of the T
allele by documenting a significant bias in its transmis-
sion from heterozygous parents to NTD offspring in 218
families. Furthermore, the size of the study population
allowed us to test for evidence of interactions between
maternal and case MTHFR genotypes and to definitively
establish that the case TT genotype is the predominant
genetic determinant of MTHFR-derived NTD risk.
Subjects and Methods
Study Population
Blood samples for genetic analysis were collected after
informed consent was obtained from the following cat-
egories of subjects: 218 individuals (120 female and 98
male) born with spina bifida or encephalocele between
1956 and 1995 (mean age 16 years on January 1, 1996),
for whom blood samples from both parents were avail-
able for genotyping; their mothers ( ); and theirn  218
fathers ( ). In the three families for which a sam-n  218
ple was available from two affected siblings, only that
obtained from the older sibling was used in the analyses
reported herein. Blood samples were also collected from
an additional 53 individuals with NTDs (23 female and
30 male), for 31 of whom maternal samples were also
obtained. Subjects were identified from the records of
the Irish Association for Spina Bifida and Hydroceph-
alus, a support group for families with an affected mem-
ber, and from a register of NTD births in the Dublin
maternity hospitals between 1976 and 1987. Diagnosis
of NTDs was based on clinical records. We are not able
to accurately estimate the proportion of NTD cases in
Ireland represented by these cases. However, as in other
such studies, the method of case recruitment precluded
the enrollment of embryos or fetuses lost in utero or
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neonates who died soon after birth; the case population
is therefore biased toward viable live births.
Controls
Blood samples were collected from a systematic group
of 242 women at their first antenatal clinic visit at the
Coombe Women’s, Rotunda, or National Maternity
hospitals in Dublin and have been described elsewhere
(Kirke et al. 1996; Molloy et al. 1997, 1998).
Mutation Analysis
DNA from whole blood or stored frozen buffy coats
was isolated, and MTHFR C677T genotyping was per-
formed by PCR and allele-specific restriction digestion
as described by Frosst et al. (1995). The normal and
variant alleles give rise to diagnostic HinfI fragments of
198 and 175 bp, respectively, when resolved on 2% aga-
rose gels.
Statistical Analysis
Comparisons of the relative frequencies of both the T
allele and the homozygous TT genotype between af-
fected individuals, parents, and controls were performed
by means of Fisher’s exact test to assess significance.
Because the major effect of the MTHFR locus on homo-
cysteine levels is mediated by the recessive TT genotype,
the primary tests were applied to this genotype, rather
than to the T allele frequency or the frequencies of the
other two genotypes.
Allele transmission tests compare the frequency of al-
lele transmissions and nontransmissions from hetero-
zygous parents and can be adapted to test a variety of
genetic mechanisms (Schaid 1996). Comparisons of the
frequencies of T and C allele transmissions to offspring
with NTDs from heterozygous parents (the TDT test
[Spielman et al. 1993]) were performed by means of an
exact McNemar test. Since the principal risk-conferring
genotype is considered to be the TT homozygote (i.e.,
the genetic mechanism is recessive), comparison of trans-
mitted and nontransmitted alleles was also performed
for the subset of families in which a TT outcome was
possible (i.e., families with a CC parent were excluded
from this subset). This permitted an assessment of T
allele transmission bias that was restricted to transmis-
sion events from the “at risk” matings.
In the case of a fetal disorder in which maternal alleles
may contribute directly to the condition under analysis,
and therefore to the risk, parental alleles may not, in
fact, be entirely appropriate controls. Weinberg et al.
(1998) have recently presented a log-linear model that
allows assessment of both fetal and maternal effects.
Accordingly, we have adopted this as our principal ap-
proach to analyzing allele transmission within families.
We fitted a recessive effect within their model, assuming
Hardy-Weinberg equilibrium. The log-linear model of
the fetal genotypic effect is equivalent (Weinberg et al.
1998) to the likelihood methods of Schaid and Sommer
(1994). We fitted the log-linear model by use of the
POISSON command of the general statistics package
STATA, release 5.0 (Statacorp), assuming Hardy-Wein-
berg equilibrium. Thus, in accord with the method of
Weinberg et al. (1998), the POISSON regression in-
cluded an offset term to allow for the double exposure
of the double heterozygote mating, a linear term equal
to the number of alleles carried by mother and father,
and optional modeled terms, including case TT homo-
zygosity and maternal TT homozygosity. Relative risks
and confidence intervals (CIs) were calculated directly
from the model.
Results
Association of the TT Genotype with NTD Risk
A total of 271 individuals with NTDswere genotyped,
of whom 18.8% (51) were TT homozygous, 43.9%
(119) were CT heterozygous, and 37.3% (101) were CC
homozygous. This compares with 8.3% (20) TT, 44.6%
(108) CT, and 47.1% (114) CC genotypes in the 242
controls. The frequency of the T allele is significantly
higher in affected individuals than in controls—that is,
40.6% compared with 30.6% (odds ratio [OR] 1.56;
95% CI 1.21–2.02; ). MTHFR genotypesP  .0007
clearly have a different distribution among individuals
with NTDs than among controls ( , x2, 2 df),P  .002
reflecting a deficit of the CC genotype in patients as well
as an excess of the TT genotype.
The biological hypothesis underlying the genetic in-
volvement of MTHFR variants in NTD outcome em-
phasizes the role of the biochemically thermolabile
MTHFR phenotype, which is the result of being ho-
mozygous (and not merely heterozygous) for the T allele.
Consistent with this hypothesis, the TT genotype is even
more strikingly associated with cases than controls (OR
2.57; 95% CI 1.48–4.45; ). Among individ-P  .0005
uals with NTDs, there is a nonsignificant increase in risk
for CT heterozygotes compared with CC homozygotes
(OR 1.22; 95% CI 0.8–1.8). Thermolabile TT homo-
zygotes, in turn, have a significantly greater risk than
CT heterozygotes (OR 2.33; 95% CI 1.3–4.3). Thus,
these data indicate that the TT genotype is a risk factor
for NTDs, and there is only a nonsignificant suggestion
that the CT genotype may be marginally higher in risk
than the CC genotype.
Allele Transmission
The 271 NTD patients included 218 for whom ma-
ternal and paternal DNA samples were also available.
These 218 family triads allowed us to determine the
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Table 1
Maternal, Paternal, and NTD Case Genotype Combinations
in All Triads
MATERNAL PATERNAL
NTD CASE
CC CT TT TOTAL
CC CC 36 ) ) 36
CC CT 21 17 ) 38
CT CC 18 22 ) 40
CT CT 7 25 19 51
CC TT ) 6 ) 6
TT CC ) 7 ) 7
TT CT ) 6 14 20
CT TT ) 12 5 17
TT TT ) ) 3 3
Total
Percentage
82
37.6
95
43.6
41
18.8
218
100
Table 2
Log-Linear Models of Case and Maternal Effects within Parent-Child Triads
MTHFR Genotype
Relative
Risk P Value 95% CI Overall x2
Estimated
Allele
Frequency
No effect ) ) ) 22.30 .37
Case TT 1.62 .024 1.06–2.45 17.42 .35
Case CT or TT 1.08 .654 .76–1.53 22.10 .37
Mother TT .95 .814 .60–1.49 22.25 .38
Mother CT or TT 1.15 .422 .81–1.64 21.66 .37
Combined model: 17.37 .36
Case TT 1.61 .024 1.06–2.45 ) )
Mother TT .95 .833 .60–1.50 ) )
frequencies of all possible mother-father-child MTHFR
genotype combinations (table 1), and this, in turn, per-
mitted us to investigate whether there is a bias in the
transmission of the T allele from heterozygous parents.
We applied log-linear models, which provide a powerful
test of allele transmission (Weinberg et al. 1998), to the
family data, assuming Hardy-Weinberg equilibrium (ta-
ble 2). A significant risk of NTDs is conferred by the
case TT genotype (OR 1.62; 95% CI 1.06–2.45; P 
). The NTD risk conferred by being either CT or.024
TT (i.e., reflecting the protective effect of the CC ge-
notype) was only 1.08 ( ). Thus, analysis of theP  .65
family data alone confirms a risk-conferring role for the
TT genotype that does not merely reflect population
stratification of case and control samples.
Simpler tests that directly compare frequencies of
transmitted and nontransmitted alleles were applied to
the 218 triads. These tests have the advantage that they
are simple to calculate and are robust in the presence of
Hardy-Weinberg disequilibrium; however, they have less
statistical power than the log-linear tests. Two such tests
were performed. The first was conventional TDT, which
tests allele transmission from heterozygous parents re-
gardless of potential case genotype outcome. Table 3
indicates that, from a total of 217 heterozygous parents,
the T allele is transmitted 121 times (55.8%), whereas
the C allele is transmitted only 96 times (44.2%). This
bias in T allele transmission is only suggestive of an effect
( ). However, since our hypothesis is that TT isP  .10
the major “at risk” genotype (i.e., the geneticmechanism
is principally recessive), and that much less, if any, risk
resides in the CT genotype, we do not believe the stan-
dard TDT is the most appropriate test to assess the im-
portance of the MTHFR locus.
The second test was allele transmission from parents
in families in which the parental genotypes would permit
the offspring to have a TT genotype (i.e., each parent
carries at least one T allele). Thus, only the fourth, sev-
enth, and eighth matings (i.e., , , andCT# CT TT# CT
, respectively) listed in table 1 were used forCT# TT
this test, applying the standard TDT comparison of al-
leles within these matings alone. From the 139 hetero-
zygous parents who could produce a TT offspring (in
whom the risk-conferring recessive genotype under test
could exert a pathogenic effect), the T allele is trans-
mitted 82 times (59%), whereas the C allele is trans-
mitted only 57 times (41%); this constitutes a bias to-
ward T allele transmission that is statistically significant
( ). Schaid and Sommer (1994) proposed an al-P  .04
ternative “REC” test for recessive loci; when applied to
our data, this test shows a similar, though less significant,
trend ( ).P  .12
Genotype Combinations in Families
The frequencies of the different mother-father-child
MTHFR genotype combinations in the 218 triads also
allowed us to assess the relative contribution of parental
and case MTHFR genotypes to NTD risk. The highest
TT genotype frequency, 18.8%, is observed in the af-
fected offspring; TT homozygotes constitute 13.8% and
11.9% of maternal and paternal genotypes, respectively,
compared with only 8.3% in controls (table 4). This
suggests that it is the case TT genotype, rather than the
maternal or paternal TT genotype, that is of paramount
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Table 3
Allele Transmission Frequencies from Heterozygous Parents in
Parent-Child Triads
GENOTYPE OF
PARENTS (n)
TRANSMISSION FREQUENCY
(n [%])
C Allele T Allele
All heterozygotes (217) 96 (44.2) 121 (55.8)
Heterozygotes whose matings
allow TT outcome (139)
57 (41.0) 82 (59.0)
Table 4
Maternal, Paternal, and NTD Case Genotype Frequencies in All
Parent-Child Triads
INDIVIDUAL n
GENOTYPE (%)
CC CT TT
NTD cases 218 37.6 43.6 18.8
NTD mothers 218 36.7 49.5 13.8
NTD fathers 218 38.1 50.0 11.9
Controls 242 47.1 44.6 8.3
importance in driving NTD pathogenesis. In addition,
the CT genotype frequencies in mothers (49.5%) and
fathers (50.0%), but not in patients (43.6%), are higher
than the CT frequency observed in controls (44.6%).
This is compatible with the hypothesis that the CT ge-
notype has little or no overall impact on NTD risk to
the embryo and indicates that it is the enrichment of T
alleles in both mothers and fathers per se (because of
the frequency of TT homozygotes in the offspring rather
than as a direct effect) that is the principal risk-confer-
ring MTHFR-related genetic factor in parents.
Parental genotypic effects independent of case ef-
fects.—Recent reports establishing that the homo-
cysteine and folate status of the mother has an impact
on NTD outcome (Kirke et al. 1993; Daly et al. 1995;
Molloy et al. 1998) have highlighted the need to verify
whether the maternal MTHFR genotype has a direct
effect on NTD risk. Although modeling of maternal ef-
fects in comparison with population controls is useful,
it is subject to the criticism that the NTD families may
be drawn from a subpopulation with a different under-
lying allele frequency. Accordingly, analysis should ide-
ally be performed with the family data alone. However,
the modeling of both maternal and case effects of geno-
types within families is clearly complex. The log-linear
model allows assessment of the risks conferred by ma-
ternal and case genotypes. Maternal TT genotype does
not contribute significantly to the model ( ; ORP  .83
0.95; table 2). Neither does maternal CC have a signif-
icant protective effect ( ; table 2). Note that theP  .42
maternal and case effects fitted within the model are
independent of each other (Weinberg et al. 1998). Thus,
the log-linear modeling indicates that a TT genotype in
the embryo is the important MTHFR-mediated contrib-
utor to NTD outcome in the Irish population and pro-
vides no evidence in support of a maternal TT effect. It
is worth noting that there is no maternal or paternal
bias in the transmission of T alleles, because exactly the
same number have been inherited from mothers (n 
) as from fathers ( ) in those cases for which76 n  76
the parental origin of the T allele is unambiguous. This
strongly suggests that parental genotypes do not play a
role in NTD etiology through biased genomic imprinting
of the MTHFR gene.
Inspection of table 1 reveals that, among matings in
which one parent is TT and the other CT, there is an
excess of TT outcomes when the mother is TT, but a
deficit when the father is TT. This difference is statisti-
cally significant ( ). There is no obvious expla-P  .02
nation for this disparity, because there is an excess of
TT outcomes among double heterozygote matings, in
which the mother is also a CT. It is unlikely to reflect a
parent-specific segregation distortion, because approxi-
mately equal numbers of these reciprocal matings give
rise to offspring with NTDs. Either this is merely a
chance finding or the paternal TT genotype contributes
functionally to NTD etiology—for example, through a
complex imprinting mechanism. However, as outlined
above, we could find no obvious evidence for such
imprinting.
Mother-child genotype combinations.—Although the
maternal TT genotype, in general, has no appreciable
influence on NTD frequency as an independent risk fac-
tor, it could be important when other folate-related risk
factors are present, including the TT genotype in the
embryo. To establish whether the maternal genotype has
any measurable effect on the NTD risk of TT embryos,
we calculated the observed and expected frequencies of
the 249 case TT–mother genotype combinations in our
study (table 5).
Expected frequencies were calculated in two ways:
The first method, “population expectation,” makes no
a priori assumption about the case TT frequency and
uses the T and C allele frequencies of the control pop-
ulation to calculate the expected frequency of TT cases,
and hence the expected case TT–mother TT and case
TT–mother CT combinations. Thus, the expected fre-
quency of the case TT–mother CT combination is
, a figure that is(0.306# 0.306)# 0.694  6.50%
computed by multiplying the expected frequency of the
case TT genotype (i.e., the product of the population
frequencies of its component alleles) by the population
frequency of the mother’s nontransmitted allele (in this
case, C).
The second method, “conditional expectation,” takes
into account the observed elevation in case TT frequency
and simply calculates the expected frequencies of pos-
sible case TT–mother genotype combinations by mul-
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Table 5
Observed and Expected Frequencies of Mother-Child Genotype Combinations
GENOTYPE OBSERVED POPULATION EXPECTATION CONDITIONAL EXPECTATION
Mother Child Number % % OR 95% CI % OR 95% CI
TT TT 20 8.03 2.86 2.98 1.2–7.2 6.14 1.33 .7–2.7
CT TT 30 12.05 6.50 1.97 1.0–3.7 13.94 .85 .5–1.4
TT CT 15 6.02 6.50 .92 .4–1.9 6.45 .93 .5–1.9
CT CT 73 25.30 21.24 1.26 .8–1.9 21.08 1.27 1.0–2.3
CC CT 27 10.84 14.74 .70 .4–1.2 14.63 .71 .4–1.2
CT CC 29 11.65 14.74 .76 .5–1.3 11.55 1.01 .6–1.7
CC CC 65 26.10 33.43 .70 .5–1.0 26.20 1.00 .7–1.4
Total ) 249 100 100 ) ) 100 ) )
tiplying the actual case TT frequency by the control pop-
ulation frequency of the nontransmitted maternal allele
(i.e., 30.6% and 69.4% for the T and C alleles, respec-
tively). Note that, in both of these methods, the popu-
lation frequency of the maternal allele that is transmitted
to the child is not included in the calculation, because
it is the fixed sine qua non that defines the relationship
under analysis, and therefore has a mandated frequency
of 100%.
Applying these frequency calculations to all seven pos-
sible case-mother genotype combinations permitted rel-
ative risks for each to be calculated (table 5). By the
population expectation method, which provides an es-
timate of the level of risk relative to the general popu-
lation, the case TT–mother TT combination has a rel-
ative risk of 2.98, whereas there is a lower, but still
significant, risk of 1.97 for case TT–mother CT com-
binations. These risk values are, respectively, higher and
lower than that conferred to the affected child by the
TT genotype when it is considered independently of the
maternal genotype (OR  2.57), the calculation of
which was based on the observed genotype frequencies
in the full 271-subject case group. To test whether these
calculations reflect a significant excess of TT mothers of
TT offspring (in comparison to CT mothers of TT off-
spring), we compared the frequency with which the non-
transmitted allele in mothers of TT cases is a T allele
( ) with the T allele frequency in the20 of 50  40.0%
control population ( ). This in-148 of 484  30.6%
creased incidence (OR 1.51; 95% CI 0.83–2.75; P 
) defines an excess of TT mothers and is therefore.20
suggestive of additional risk in TT mother–TT embryo
combinations, which is attributable to the maternal ge-
notype but is not statistically significant. The risk esti-
mates calculated by the conditional expectation method
provide a more direct means of assessing the above, since
the effect of the maternal genotype is isolated; conse-
quently, any bias toward a particular maternal genotype
would indicate that it confers a specific risk in addition
to that conferred by the genotype of the embryo itself.
From table 5it is clear that the excess of mothers of TT
embryos who themselves have the TT genotype (OR
1.33; 95% CI 0.7–2.7) is again only suggestive and is
also not statistically significant. Thus, our data do not
support a strongmaternal genotypic effect in the etiology
of MTHFR-related NTDs.
Discussion
Recently, it has been proposed that a common, mildly
dysfunctional “thermolabile” variant of the folate-
dependent enzyme MTHFR is a genetic factor that ac-
counts for at least some of the observed association of
NTDs with low maternal folate status and high plasma
homocysteine concentrations. Furthermore, the obser-
vation that individuals with the variant have an in-
creased folate requirement may explain at least some of
the prevention of NTD pregnancy outcome that can be
achieved with periconceptional folic acid supple-
mentation.
The homozygous thermolabile “TT” MTHFR geno-
type was first identified as a risk-conferring genotype in
NTD pregnancy outcome by us (Whitehead et al. 1995)
and by a group in The Netherlands (van der Put et al.
1995); further evidence in support of a pathogenic role
for the TT genotype in NTD etiology was presented by
Ou et al. (1996) and Christensen et al. (1997). A number
of articles, however (de Franchis et al. 1995; Papapetrou
et al. 1996;Wilcken andWang 1996;Mornet et al. 1997;
Speer et al. 1997; Koch et al. 1998), either reported a
lack of association between the TT genotype and NTDs
or challenged the validity of the studies that supported
a positive association on the grounds that they were
based on a case-control design that is inherently vul-
nerable to sampling error. Both de Franchis et al. (1995)
and Wilcken and Wang 1996 cautioned that population
frequencies of the TT genotype vary widely among white
populations and that larger numbers of subjects would
be required to make valid population-specific statements
regarding the level of risk conferred by this genotype.
The others also presented data that failed to show a
statistically significant association of the TT genotype
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with NTD outcome, regardless of whether analytical
methods based on population frequencies or alternatives
such as allele TDT were applied. The number of subjects
recruited into each of these latter studies was, however,
very small.
On the basis of the data presented here, we estimate
the attributable fraction of NTDs due to the MTHFR
TT genotype in Ireland at 11.4%, assuming a causal
relationship between the TT genotype and these mal-
formations, and by means of the formula of Kelsey et
al. (1986) for computing attributable fraction. The high-
est estimate of population-attributable fraction in any
study to date is 19% (Ou et al. 1996). Clearly the great
majority of NTDs, including a majority of those that
are folate preventable, must be driven by other, non–
TT-related etiologic factors. As the vast majority of TT
homozygotes do not have NTDs, it is also clear that the
TT genotype is a risk factor with very low penetrance.
It is, therefore, not surprising that studies involving very
small numbers of patients have failed to show any as-
sociation between TT genotype status and NTDs. Given
these facts, it is apparent that large numbers of individ-
uals with NTDs (and their parents) are needed for either
genotype association studies or the allele TDT to have
sufficient statistical power to enable definitive conclu-
sions regarding the causative role of the TT genotype.
The requisite numbers of subjects can be generated by
performing larger “single-center” studies within genet-
ically homogeneous populations or by the pooling of
data from several independent association studies to per-
form a meta-analysis, such as that recently reported by
van der Put et al. (1997a). We believe that the latter
method is not an ideal solution to the need for large
numbers of subjects for investigating the relationship
between the TT genotype and NTDs, since it would
draw cases and controls from ethnically distinct groups
that are known to have very different MTHFR allele
frequencies and would not be controlled for national or
region-specific environmental factors, such as folate con-
sumption, that are critical for evaluating genetic factors
linked to nutrition. In addition, meta-analyses may be
biased in favor of positive outcome, because negative
studies are generally underreported in the literature.
The MTHFR genotype data presented herein are, to
our knowledge, derived from the analysis of the largest
number ( ) of NTD cases reported to date, andn  271
reinforce the hypothesis that the embryonic TT genotype
is a significant genetic risk factor for NTD pregnancy
outcome. The level of risk (OR 2.57; ) is lowerP ! .0005
than that reported by us in our initial study of 82 cases
(OR 3.47) but is similar to that observed in a subsequent
enlarged study of 153 cases (OR 2.61); each of these
studies was based on a subset of the NTD cases analyzed
here (Whitehead et al. 1995; Kirke et al. 1996). We
therefore consider it to be a good estimate of the risk
conferred by the TT genotype in the Irish population.
In establishing whether a genetic condition is, in fact,
caused by a particular candidate allele, tests of allele
transmission within families rather than case-control
comparisons are considered by many to provide a better
standard of proof. Such tests use the nontransmitted
parental alleles as controls and thereby avoid the false
conclusions that may result from genetic stratification
between case and control populations. Three recent
studies of T allele transmission to NTD offspring (Pa-
papetrou et al. 1996; Speer et al. 1997; Koch et al. 1998)
were based on small numbers—24, 58, and 70 hetero-
zygous parents, respectively, who transmitted 12, 31,
and 34 T alleles—and concluded that there is no evi-
dence in support of a causative relationship between the
T allele and NTD phenotype. In view of our contention
that the TT genotype is a low-penetrance genetic factor
acting in the context of a large majority of NTD cases
that have arisen via other mechanisms, it is extremely
unlikely that any study involving relatively small num-
bers of families, such as those reported in the literature
thus far, could have generated a statistically significant
result, either positive or negative, by using the TDT.
Furthermore, the test has hitherto been applied to the
transmission of the T allele from all heterozygous par-
ents, apparently without consideration of the possible
genotype outcome in the offspring, which is, of course,
also dependent on the genotype of the other parent. Since
the case genotype frequencies in our study established
that TT, but not CT, is elevated relative to controls, the
former is clearly the principal risk-conferring genotype.
Thus, we postulate that the thermolabile MTHFR allele
essentially acts in a recessive manner to generate a mildly
dysfunctional phenotype in TT homozygous embryos
that is potentially pathogenic when folate levels are low.
This is consistent both with the biochemistry of the ther-
molabile variant and with our understanding of the
pathophysiology of NTDs. We therefore believe that as-
sessment of the genetic impact of the T allele in NTD
causation requires that the TDT be used in a manner
that takes into account the likely underlying biological
mechanism. When we applied a modified TDT, which
accommodates the proposed biochemical mechanism, to
our data set, we observed a T allele transmission rate of
59%, a bias that is statistically significant ( ). InP  .04
addition, log-linear models of a recessive effect dem-
onstrated a significant role for the case TT genotype
( ). These results powerfully underscore the con-P  .02
clusion previously reached from association studies that
the case TT genotype is a genetic risk factor for NTD
outcome.
The TT genotype frequency in individuals with NTDs
and their mothers can be used to establish the relative
importance of the case and maternal genotypes to the
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cause of NTDs. In our 218 triads, the case and maternal
TT frequencies are 18.8% and 13.8%, respectively, com-
pared with 8.3% in the controls. It is clear from these
figures that MTHFR-associated NTD pathogenesis in
the Irish population is principally dependent on the TT
genotype status of the embryo rather than the mother.
Log-linear modeling confirmed that the maternal TT ge-
notype is not a significant independent contributor to
NTD risk ( ). This conclusion is contrary to theP  .83
conclusion that would be reached by considering the
data reported by van der Put et al. (1995), in which the
case and maternal TT frequencies were 13% and 16%,
respectively. This Dutch study, however, was based on
only 55 case and 70 maternal genotypes, and it is unclear
how many of these constituted mother–affected off-
spring pairs. In a subsequent report from the same group
using only 51 such pairs (van der Put et al. 1996), the
frequency of TT homozygotes was even more skewed,
19.6% TT in mothers and 13.7% TT in cases. There
are two possible explanations for this apparent discrep-
ancy. It is possible, but perhaps unlikely, that the bio-
logical mechanism leading to a failure to close the neural
tube differs between the populations in Ireland and The
Netherlands because of additional, as yet undefined, nu-
tritional and/or genetic factors, specific to the latter
country, that act through the mother. Alternatively, the
small sample size in the Dutch study may have produced
an excess of the TT genotype in mothers relative to that
observed in cases, either by chance or because of a dis-
proportionate loss of TT embryos prior to birth. In Ire-
land, the prevailing legal and social constraints on pre-
natal screening and elective abortion are such that it is
unlikely that our case population has been subjected to
genotype-specific preterm loss through medical inter-
vention. We therefore believe that our data provide
strong evidence that the embryonic TT genotype is of
paramount importance in determining NTD outcome.
The question of the extent, if any, to which the ma-
ternal MTHFR TT genotype actively contributes to
NTD outcome could also be addressed with the large
number ( ) of mother–NTD case pairs in ourn  249
study. Hyperhomocysteinemia is a maternal phenotype
that has been associated with NTD outcome (Mills et
al. 1995), and there is good evidence from genotype-
nutrition interaction studies that TT homozygotes are
at risk of hyperhomocysteinemia when plasma folate
concentrations are low and that the thermolabile
MTHFR enzyme may further depress plasma folate lev-
els that are already low (Harmon et al. 1996; Jacques
et al. 1996). A plausible biological hypothesis exists,
therefore, to explain how the maternal TT genotype
could play a particular pathogenic role in NTDs, either
by limiting the supply of folate to the embryo or by
facilitating the accumulation and increased transfer to
the embryo of homocysteine, high concentrations of
which can disrupt neural tube closure in experimental
models (Rosenquist et al. 1996). However, it is also plau-
sible that the pathogenic impact of the TT genotype in
the context of low folate is exclusive to the embryo (see
above discussion) and therefore that hyperhomocystei-
nemia (and the TT genotype) is more prevalent in
women who give birth to a child with an NTD merely
because the excess number of TT homozygotes in the
NTD offspring drives up the frequency of the T allele,
and TT homozygotes, in the mothers.
We have used two methods to calculate the expected
frequencies of the various mother–affected offspring ge-
notype combinations, an approach that is based on con-
trol C and T allele frequencies and is adjusted to allow
for the fact that the mother inevitably shares one T allele
with her child. These have been compared to the ob-
served frequencies of the genotype combinations. Our
data, derived from a population expectation method,
indicate that the risk conferred by a TTmother–TT child
combination (OR 2.98) is greater than that conferred
by a CTmother–TT child combination (OR 1.97). How-
ever, the difference between the combinations is not sta-
tistically significant. In a recent report, van der Put et
al. (1996) claimed that the frequency of the maternal
TT–case TT genotype combination was significantly
higher than expected (5.9% observed compared with
0.9% predicted from control allele frequencies) in a
group comprising 51 Dutch mother–NTD child pairs.
This claim, however, was based on only three such ge-
notype combinations identified within a study popula-
tion in which the proportion of TT mothers relative to
TT offspring is unexpectedly high. The analytical
method used by van der Put et al. (1996), which was
not clearly described in their report, also underestimated
the expected frequencies of the rarer genotype combi-
nations, especially the maternal TT–case TT combina-
tion (probably due, in part, to the use of control TT
frequencies that are belowHardy-Weinberg predictions),
and consequently leads to inflation of the risk estimates
for these combinations. Recalculation of the data pub-
lished by van der Put et al. 1996 by our population
expectation method yields an expected maternal
TT–case TT frequency of 1.68%, given the Dutch con-
trol T allele frequency of 25.6%, rather than the ex-
pected frequency of 0.9% reported; as a result, the OR
based on the very small data set from the Dutch group
fell from 6.1 to 3.67 and was no longer significant (95%
CI 0.76–17.74). When we used our conditional expec-
tation method (which is a better indicator of the poten-
tial maternal contribution) to recalculate the Dutch data,
the expected frequency of the maternal TT–case TT
combination was 3.51%, and the OR was even lower
and less significant (OR 1.78; 95% CI 0.44–7.16)
We applied several other analytical methods to our
data set, all of which yielded nonsignificant indications
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that the maternal genotype plays, at most, a modest role
in NTD pathogenesis. We believe that this issue can only
be resolved either by studies of much larger numbers of
mother–child pairs or by the application of the TDT to
three-generation families that include heterozygous ma-
ternal grandparents of NTD offspring (in which being
a mother of an NTD child is the condition under anal-
ysis), an approach that has been suggested by others
(Mitchell 1997).
On the basis of the evidence presented here, it is clearly
the TT genotype status of the developing embryo, rather
than the TT genotype status of its mother, that is the
critical genetic determinant of MTHFR-related NTD
risk. Our data do not exclude the possibility that the
maternal TT genotype may confer an additional risk to
a TT embryo over and above the risk that can be at-
tributed to the genotype of the embryo itself, but the
effect of this is probably comparatively small. Our own
previous work has indicated both that the maternal TT
genotype is associated with lower red blood cell folate
and that lower red blood cell folate increases NTD risk
(Daly et al. 1995; Molloy et al. 1997). However, we
have also established that plasma and red blood cell
folate levels tend to be reduced in women who give birth
to NTD offspring, regardless ofMTHFR genotype (Mol-
loy et al. 1998). Therefore, the maternal TT genotype
might become only a modest risk factor by further de-
pressing maternal folate levels that are already below a
nominal threshold at which risk is enhanced. If such is
the case, it is likely to be relevant in only a small pro-
portion of NTD-affected pregnancies. Indeed, of the 50
TT offspring in this study for whom maternal MTHFR
genotypes are known, 20 have TT mothers, rather than
the expected 15; a simplistic evaluation would therefore
conclude that only 5 (10%) of these offspring have an
NTD that may be attributable to additional risk con-
ferred by the maternal TT genotype. At present, we favor
a biological model of MTHFR-driven NTD causation
in which the mother’s folate status, which may be mildly
compromised by having a TT genotype, determines the
exposure of the embryo to pathogenic challenges that it
is particularly ill-equipped to overcome if it is a TT ho-
mozygote expressing the thermolabile form of the
enzyme.
In summary, this study provides compelling evidence
that the MTHFR TT genotype is a risk factor for NTDs,
at least in populations in which folate nutrition is su-
boptimal. We estimate that the population-attributable
fraction in Ireland is ∼12%. Although the majority of
NTDs must, therefore, be caused by other genetic and/
or environmental factors, we nevertheless achieved sta-
tistical significance with methods based on comparisons
with population controls and with methods based on
log-linear modeling and allele transmission biases within
families. Furthermore, we have established that the case
TT genotype is the principal determinant of MTHFR-
related NTD outcome and that the maternal TT geno-
type plays, at most, a minor role. The population-at-
tributable fraction may be !12% in countries that have
a higher dietary or supplemental folate/folic acid intake
than Ireland, but it is likely that the TT genotype is a
universal genetic risk factor for embryos under low fo-
late conditions. Future studies should be directed toward
defining the folate threshold below which the TT ge-
notype becomes potentially pathogenic, and public
health policy should incorporate directed or general folic
acid supplementation strategies that are designed to pre-
vent folate levels in at-risk pregnant women from falling
below that threshold.
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